The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Share News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 192.50
Bid: 190.00
Ask: 195.00
Change: -3.50 (-1.79%)
Spread: 5.00 (2.632%)
Open: 193.00
High: 198.00
Low: 192.50
Prev. Close: 196.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Faron Pharma Raises EUR2.5 Million; Now Has Working Capital To 2020

Tue, 27th Aug 2019 11:38

(Alliance News) - Faron Pharmaceuticals Oy on Tuesday said it has raised EUR2.5 million via share subscription and open offer.

The company raised EUR1.0 million from the issue of 859,513 shares at EUR1.19 per share pursuant to an open offer. It also received EUR380,000 from subscription of 320,000 open offer shares not taken up.

Faron additionally raised EUR1.1 million from a separate share subscription of 941,840 shares at the same issue price, taking the total raised to EUR2.5 million before expenses.

The clinical stage biopharmaceutical firm now has working capital through to early in the first quarter of 2020.

The total number of Faron shares in issue after the subscription, open offer, and further subscription shares are issued will be 39.4 million.

Shareholder Timo Syrjala subscribed for 70,000 subscription shares via his wholly owned entity, Acme Investments SPF Sarl, for EUR80,000 - plus 168,198 open offer shares. Syrjala now owns 15% stake or 5.7 million shares in Faron Pharma.

Shares in Faron were down 1.3% at 111.00 pence in London on Tuesday.

More News
9 Mar 2020 14:07

Faron Pharmaceuticals Gets Green Light For New Traumakine Trial

Faron Pharmaceuticals Gets Green Light For New Traumakine Trial

Read more
9 Mar 2020 10:26

Faron gets FDA tick from proposed design of next 'Traumakine' study

(Sharecast News) - Faron Pharmaceuticals announced on Monday that the US Food and Drug Administration (FDA) has accepted its proposed protocol design for the next 'Traumakine' study in acute respiratory distress syndrome (ARDS) patients, following its protocol submission in February.

Read more
5 Mar 2020 14:28

Faron Pharmaceuticals "Encouraged" After Latest Matins Trial Findings

Faron Pharmaceuticals "Encouraged" After Latest Matins Trial Findings

Read more
2 Mar 2020 12:04

Faron Pharmaceuticals Buys Rights For AOC3 Antagonist Platform

Faron Pharmaceuticals Buys Rights For AOC3 Antagonist Platform

Read more
2 Mar 2020 10:08

Faron Pharmaceuticals acquires rights to AOC3 inhibitors

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals has acquired rights for the potential new use of AOC3 inhibitors covered by a recently filed patent application.

Read more
6 Feb 2020 14:17

Faron Pharmaceuticals Alters Traumakine Study After US FDA Feedback

Faron Pharmaceuticals Alters Traumakine Study After US FDA Feedback

Read more
27 Jan 2020 11:22

Faron Pharma To Test Clevegen In Patients With Ovarian Cancer

Faron Pharma To Test Clevegen In Patients With Ovarian Cancer

Read more
13 Jan 2020 11:54

Faron Pharma Gets Approval For Part II Trial Of Clevegen Drug

Faron Pharma Gets Approval For Part II Trial Of Clevegen Drug

Read more
30 Dec 2019 15:39

Faron Pharma requests arbitration over Traumakine manufacturing deal

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced on Monday that, further to the update on 'Traumakine' drug substance manufacturing on 2 October, it has carried out a detailed investigation into the circumstances around manufacturing arrangements.

Read more
30 Dec 2019 10:56

Faron Pharma Files For Arbitration Amid Traumakine Deal Termination

Faron Pharma Files For Arbitration Amid Traumakine Deal Termination

Read more
11 Dec 2019 13:42

Faron Pharmaceuticals upbeat on new data from 'MATINS' study

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced new data from 'MATINS'-trial patients on Wednesday, to be presented at the ESMO Immuno-Oncology Congress 2019 in Geneva.

Read more
11 Dec 2019 10:45

Faron Pharmaceuticals Pleased With Clevegen Clinical Trial Performance

Faron Pharmaceuticals Pleased With Clevegen Clinical Trial Performance

Read more
29 Nov 2019 10:23

Faron Pharmaceuticals Inks Share Liquidity Pact With Lago Kapital

Faron Pharmaceuticals Inks Share Liquidity Pact With Lago Kapital

Read more
28 Nov 2019 11:56

Faron Pharmaceuticals Says US Regulator Approves Clevegen Drug Status

Faron Pharmaceuticals Says US Regulator Approves Clevegen Drug Status

Read more
21 Nov 2019 12:56

Faron Pharmaceuticals Applies For Nasdaq First North Growth Listing

Faron Pharmaceuticals Applies For Nasdaq First North Growth Listing

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.